However, the EGFR mutation (+) group did not: BMA (−) n = 11, median post-bone metastasis survival 24.1 months (95% CI: 7.0–N/A); BMA (+) n = 28, median post-bone metastasis survival 31.0 months (95% CI: 17.6–36.5) (p = 0.49) (Figure 3E). This evidence concerns the gene EGFR and bone metastasis.